



Supplementary figure 8


A




B




C




D



E





Supplementary figure 8. *In vivo* injected NK cells require IL-15 support. (a) Schematic overview of group allocation and experimental setup of the *in vivo* NK cell activation model (n = 7 per group). (b) Percentage of CD56⁺ cells within hCD45⁺ cells from blood (day 1, 4 and 7) and spleen and liver (day 7). (c) Absolute numbers (blood, spleen, bone marrow) and frequency (liver) of hCD45⁺ cells in mice treated with or without DC-complete vaccination and supported with/without IL-15 at day 1, 4 (blood) and 7 (blood, spleen, bone marrow, liver). (d, e) MFI of CD69 on NK cells of mice treated with or without DC-complete vaccination and supported with/without IL-15 at day 1 (d) and followed over time (e). (f-h) Expression of CD56, NKG2A and Nkp46 on NK cells in mice vaccinated with or without DC-complete vaccination and supplemented with/without IL-15 support at day 1, 4 and 7 on NK cells isolated from blood, spleen and liver respectively. (i) Expression of TRAIL and CD25 on NK cells in mice vaccinated with or without DC-complete vaccination and supplemented with/without IL-15 at day 1. (j) Composition of the DC-complete vaccine used in this *in vivo* NK cell activation model. (k) Expression of co-stimulatory molecules CD80, CD83 and CD86 on the matured DC-complete vaccine before *in vivo* injection. Statistical analysis were performed using Two-Way ANOVA followed by Bonferroni correction comparing selected pairs of means (c, d, f-h) or one-way ANOVA followed by Dunn's correction comparing all pairs of means (e). **P* < 0.05, ***P* < 0.01. ****P* < 0.001.